Anika Therapeutics | ANIK - Current Liabilities


Anika Therapeutics reported $22.15M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Abbott USD 18.38B 1.88B Mar/2026
Agenus USD 231.82M 17.42M Jun/2026
Agios Pharmaceuticals USD 70.22M 11.37M Jun/2026
Anika Therapeutics USD 22.15M 1.18M Jun/2026
Arrowhead Research USD 283.35M 11.87M Jun/2026
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Halozyme Therapeutics USD 344.44M 18.77M Jun/2026
Heron Therapeutics USD 92.14M 1.63M Jun/2026
Insmed USD 438.74M 77.74M Jun/2026
Integra LifeSciences USD 330.88M 15.96M Jun/2026
Intrexon USD 23.02M 38K Jun/2024
J&J USD 54.9B 2.82B Jun/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
Ligand Pharmaceuticals USD 46.74M 6.07M Jun/2026
MacroGenics USD 108.82M 12.88M Jun/2026
Merit Medical Systems USD 264.93M 48.06M Jun/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 31.93B 1.92B Jun/2026
Smith & Nephew USD 2.05B 510M Jun/2026
Stryker USD 6.68B 369M Jun/2026
Veracyte USD 62.74M 6.62M Jun/2026
Xencor USD 81.86M 8.41M Jun/2026
Zimmer Biomet Holdings USD 3.01B 149.2M Jun/2026